IA

Imam Akhter

Active Director Director DIN 03600034
DIN 03600034 First appointment Sep 2011 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2011
Shareholding value •••• Premium profile

About Imam Akhter

Data last updated:

Imam Akhter is a Director at Etios Pharmaceuticals Private Limited (since 2011). The company operates in Trading. Etios Pharmaceuticals Private Limited reported revenue of ₹34.2 Lakh (FY 2024).

DIN 03600034
Primary Designation Director
Industry Trading
First Appointment 05 Sep 2011
Oldest Company Age 15 yrs
Largest company Etios Pharmaceuticals Private Limited · ₹34.2 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director05 Sep 20112011₹34.2 Lakh (FY 2024)Active

Board colleagues of Imam Akhter

NameDINCompanyDesignation
Mukesh Kumar Singh03600048Etios Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Etios Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Imam Akhter

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Imam Akhter

Imam Akhter currently holds 1 directorship: Etios Pharmaceuticals Private Limited (Director, since 05 Sep 2011, revenue ₹34.2 Lakh (FY 2024)).

Imam Akhter was first appointed on 05 Sep 2011 as Director at Etios Pharmaceuticals Private Limited.

The current boards of Imam Akhter's companies include Mukesh Kumar Singh (Etios Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available